Claim · 2021-04-15 · snapshot · Stated in source · Supported

Recursion's IPO prospectus (15 April 2021) names Christopher Gibson as its Chief Executive Officer and states that he had held the role since the company's founding in November 2013.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Chris Gibson → held role at → Recursion Pharmaceuticals

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Chris Gibsonheld role at ↓Recursion Pharmaceuticals

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2021-04-15 · snapshot Records dated 2021 →
Role: Chief Executive Officer

Scope and limitsA historical role snapshot. The record does not establish the end of the role or any later title.

The evidence 02

primary sourceSupports the claim

Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock

Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Christopher Gibson, Ph.D., is our co-founder and Chief Executive Officer”

Location in source Management, "Executive Officers"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (10 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A12) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

primary sourceSupports the claim

Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock

Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Paraphrase

the same sentence continues that he has held the role since the company's founding in November 2013.

Location in source Management, "Executive Officers", same sentence

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The paraphrase is Selekoa’s, written from the text retrieved for the candidate pack on 2026-10-30; it is not a quotation and was not machine-matched. Paraphrased because the filing encodes the apostrophe in "company's" as a Windows-1252 character reference () that the text extraction does not render, so the verbatim span cannot be matched against the retrieved text. A cross-family machine check (2026-10-30, item A12) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An institutional role with explicitly scoped time: snapshot, sourced interval, or unknown dates. No continuing appointment is implied.

Date. A role stated in the prospectus of this date; the start as stated (November 2013) is the company's statement. No continuing appointment is implied.

Record ID aib-co-gibson-recursion-ceo-2021